TARDBP and amyotrophic lateral sclerosis: By the same token that we have assessed interventions in well‐established ALS‐relevant pathways, new trials, including those that target nuclear export, TDP‐43 mislocalization, and other RNA processing defects, among others, should not be judged solely on the basis of early phase studies that are upcoming.